Expression of Serine Protease Matriptase in Renal Cell Carcinoma: Correlation of Tissue Microarray Immunohistochemical Expression Analysis Results with Clinicopathological Parameters

Abstract

Serine protease matriptase (matriptase) cleaves and activates proteins implicated in the progression of cancer and represents a potential therapeutic target. Immunohistochemical analysis of matriptase was performed in tissue microarrays of 168 renal cell carcinomas (RCCs). All subtypes of RCC showed significant immunohistochemical expression of matriptase. In contrast, no expression occurred in areas of RCC with sarcomatous differentiation (SRCC) and in normal collecting tubules. The matriptase scores were significantly higher in papillary RCC (341) and clear cell RCC with granular cell differentiation (GRCC; 324) than in other histologic subtypes of RCC. In GRCC, matriptase scores were correlated with TNM staging and nuclear grading. Matriptase was overexpressed in all subtypes of RCC, and matriptase scores could distinguish between conventional clear cell RCC, GRCC, and SRCC.

Keywords

serine protease matriptase renal cell carcinoma chromophobe type clear cell type granular cell differentiation

Get full access to this article

View all access options for this article.

References

1. Sweeney P , Wood CG , Pisters LL , Slaton JW , Vaporciyan A , Munsell M , Carpenter S , Putnam J , Swisher SG , Walsh G , Swanson D , Dinney CP . Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urolo Oncol 21:327-333, 2003

2. Bonsib SM , Gibson D , Mhoon M , Greene GF . Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24:451-458, 2000

3. Atkins MB , Regan M , McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10:6342S-6346S, 2004

4. Flanigan RC . Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 10:6335S-6341S, 2004

5. Shi YE , Torri J , Yieh L , Wellstein A , Lippman ME , Dickson RB . Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res 53:1409-1415, 1993

6. Lin CY , Wang JK , Torri J , Dou L , Sang QA , Dickson RB . Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J Biol Chem 272:9147-9152, 1997

7. Lin CY , Anders J , Johnson M , Dickson RB . Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 274:18237-18242, 1999

8. Lin CY , Anders J , Johnson M , Sang QA , Dickson RB . Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 274:18231-18236, 1999

9. Zhang Y , Cai X , Schlegelberger B , Zheng S. Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24-*q25 by in situ hybridization. Cytogenet Cell Genet 83: 56-57, 1998

10.

10. Takeuchi T , Shuman MA , Craik CS . Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci USA 96:11054-11061, 1999

11.

11. Tanimoto H , Underwood LJ , Wang Y , Shigemasa K , Parmley TH , O'Brien TJ . Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol 22:104-114, 2001

12.

12. Oberst M , Anders J , Xie B , Singh B , Ossandon M , Johnson M , Dickson RB , Lin CY . Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 158:1301-1311, 2001

13.

13. Takeuchi T , Harris JL , Huang W , Yan KW , Coughlin SR , Craik CS . Cellular localization of membranetype serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275:26333-26342, 2000

14.

14. Lee SL , Dickson RB , Lin CY . Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275:36720-36725, 2000

15.

15. Fischer K , Lutz V , Wilhelm 0 , Schmitt M , Graeff H , Heiss P , Nishiguchi T , Harbeck N , Kessler H , Luther T , Magdolen V , Reuning U. Urokinase induces proliferation of human ovarian cancer cells: Characterization of structural elements required for growth factor function. FEBS Lett 438:101-105, 1998

16.

16. Corps AN , Sowter HM , Smith SK . Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int J Cancer 73:151-155, 1997

17.

17. Sowter HM , Corps AN , Smith SK . Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer 83:476-480, 1999

18.

18. Gabra H , Taylor L , Cohen BB , Lessels A , Eccles DM , Leonard RC , Smyth JF , Steel CM . Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 72:367-375, 1995

19.

19. Gabra H , Watson JE , Taylor KJ , Mackay J , Leonard RC , Steel CM , Porteous DJ , Smyth JF . Definition and refinement of a region of loss of heterozygosity at 1 lq23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 56:950-954, 1996

20.

20. Davis M , Hitchcock A , Foulkes WD , Campbell IG . Refinement of two chromosome 11 q regions of loss of heterozygosity in ovarian cancer. Cancer Res 56: 741-744, 1996

21.

21. Connolly KC , Gabra H , Millwater CJ , Taylor KJ , Rabiasz GJ , Watson JE , Smyth JF , Wyllie AH , Jodrell DI . Identification of a region of frequent loss of heterozygosity at 1 q24 in colorectal cancer. Cancer Res 59:2806-2809, 1999

22.

22. Gudmundsson J , Barkardottir RB , Eiriksdottir G , Baldursson T , Arason A , Egilsson V , Ingvarsson S. Loss of heterozygosity at chromosome 11 in breast cancer: Association of prognostic factors with genetic alterations. Br J Cancer 72:696-701, 1995

23.

23. Gentile M , Olsen K , Dufmats M , Wingren S. Frequent allelic losses at 1 Iq24.1-q25 in young women with breast cancer: Association with poor survival. Br J Cancer 80:843-849, 1999

24.

24. Hampton GM , Penny LA , Baergen RN , Larson A , Brewer C , Liao S , Busby-Earle RM , Williams AW , Steel CM , Bird CC . Loss of heterozygosity in cervical carcinoma: Subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci USA 91:6953-6957, 1994

25.

25. Akhtar M , Kardar H , Linjawi T , McClintock J , Ali MA . Chromophobe cell carcinoma of the kidney: A clinicopathologic study of 21 cases. Am J Surg Pathol 19:1245-1256, 1995

26.

26. Cheville JC , Lohse CM , Zincke H , Weaver AL , Blute ML . Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612-624, 2003

27.

27. Oberst MD , Singh B , Ozdemirli M , Dickson RB , Johnson MD , Lin CY . Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 51:1017-1025, 2003

28.

28. Lam JS , Belldegrun AS , Figlin RA . Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 10:6304s-6309s, 2004